Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PACB vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

BMRA Overall Winner 6-Pillar Tally: PACB 1 – 4 BMRA (1 Tie) Matrix Metrics: PACB 4 – 4 BMRA

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 41.4); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PACB vs BMRA
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.88
-4.34% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.24β · 110% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 15.0 Fund 36.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.4 · SMA20: $2.29 · SMA50: $2.02
BMRA NASDAQ Head-to-Head Winner
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (PACB 1 – 4 BMRA)

Columns: Metric · PACB · BMRA
1. Valuation Multiples BMRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.8x 1.1x
2. Growth & Scale PACB
Revenue Growth (YoY) +5.5% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $161M $4.3M
Market Cap $615.1M $6.0M
3. Profitability & Quality BMRA
Gross Margin 27.7% 0.9%
Operating Margin -333.0% -125.2%
Net Profit Margin -81.3% -115.5%
Return on Equity (ROE) -929.3% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$150M -$3.2M
Cash Flow Margin -93.2% -73.5%
Net Cash / Leverage $649M Net Debt $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.6% (47th %ile) N/A (N/A)
Put/Call OI Skew 0.19x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PACB (4) vs BMRA (4)
Institutional Metric PACB BMRA Criterion Row Edge
Market Capitalization
Scale
$615.1M $6.0M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+5.5% -8.3% Higher Growth PACB
Operating Margin (TTM)
Profitability
-333.0% -125.2% Higher Margin BMRA
Net Profit Margin
Profitability
-81.3% -115.5% Higher Margin PACB
Return on Equity (ROE)
Capital Efficiency
-929.3% -113.8% Higher ROE BMRA
52-Week Range Position
Momentum
34% ($1–$3) 4% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
2.24β · 110% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$161M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
27.7% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.8x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($649M Net Debt) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +36.57 pp
PACB: +8.38% · BMRA: -28.19%
3M Horizon PACB +81.44 pp
PACB: +64.47% · BMRA: -16.97%
6M Horizon PACB +104.0 pp
PACB: +63.04% · BMRA: -40.96%
1Y Horizon PACB +61.89 pp
PACB: +15.03% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PACB Revenue BMRA Revenue PACB Op. Margin BMRA Op. Margin Margin Leader
FY2019 $90M $10M -110.6% -46.4% BMRA
FY2020 $80M $10M -132.3% -41.0% BMRA
FY2021 $130M $10M -161.2% -104.2% BMRA
FY2022 $130M $20M -239.4% -24.0% BMRA
FY2023 $200M $10M -166.8% -135.3% BMRA
FY2024 $150M $10M -308.0% -117.6% BMRA
FY2025 $160M $10M -346.2% -96.7% BMRA
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PACB vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 41.4); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PACB cumulative revenue shifted +77.8% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

BMRA screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 110% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.